Sentences with phrase «of myeloproliferative»

Substantial progress has been made in our understanding of the pathogenetic basis of myeloproliferative neoplasms.

Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria

There are a number of different types of myeloproliferative disorders.

At the end of your myeloproliferative neoplasms treatment, you'll schedule a survivorship visit with your oncologist and nurse practitioner.

Relevance to practice: Identification of the Val617Phe JAK2 mutation lays the foundation for new approaches to the diagnosis, classification, and treatment of myeloproliferative disorders.

The discovery of a new therapeutic target for certain kinds of myeloproliferative disease is, without doubt, good news.

Contemporary Management of Myeloproliferative Neoplasms Brady L. Stein and Brandon J. McMahon, Eds.

Not exact matches

«We think this study now provides a comprehensive model of how thrombopoietin controls platelet production, and perhaps gives some insight into the biology and mechanism behind specific myeloproliferative disorders,» Dr Ng said.

Next on 23andMe's agenda: applying the same approach to rare cancers, such as sarcoma and a group of blood cancers called myeloproliferative neoplasms, that are difficult to study but that might be ideally suited to this kind of analysis.

«Microenvironment of hematopoietic stem cells can be a target for myeloproliferative disorders.»

The findings, published today in Nature, demonstrate that these myeloproliferative neoplasias only appear after damage to the microenvironment that sustains and controls the hematopoietic stem cells — the cells that produce the cells of the blood and the immune system.

The team has shown that the microenvironment that controls hematopoietic stem cells can be targeted for the treatment of a set of disorders called myeloproliferative neoplasias, the most prominent of which are chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myelogenous leukemia (CML).

He has extensive experience treating patients with blood cancers and holds a particular interest in chronic myeloid leukemia and myeloproliferative neoplasms, a group of blood cancers related to leukemia.

Myeloproliferative neoplasms (MPN) are diagnosed in around 3,300 UK patients every year and cause an overproduction of blood cells creating a significant impact on quality - of - life, with symptoms such as night sweats, itching and tiredness.

Based on empirical data obtained in cases of chronic myeloid leukemia, a myeloproliferative syndrome controlled by the immune system, and in solid tumors, we observe both the possible contribution of innate CD8 (+) T cells to cancer disease control and their susceptibility to tumor immune subversion.

Title: Atopic dermatitis - like disease and associated lethal myeloproliferative disorder arise from loss of notch signaling in the murine skin Authors: Dumortier A, Durham AD, Di Piazza M, Vauclair S, Koch U, Ferrand G, Ferrero I, Demehri S, Song LL, FarrAG, Leonard WJ, Kopan R, Miele L, Hohl D, Finke D, Radtke F Date: February 2010 Publication Details: PLoS One.

We investigated the role of the cytoplasmic tyrosine kinase JAK2 in patients with a myeloproliferative disorder.

Background: Human myeloproliferative disorders form a range of clonal haematological malignant diseases, the main members of which are polycythaemia vera, essential thrombocythaemia, and idiopathic myelofibrosis.

Interpretation: A single acquired mutation of JAK2 was noted in more than half of patients with a myeloproliferative disorder.

4/7/2008 From Bench to Bedside in One Year: Stem Cell Research Leads to Potential New Therapy for Rare Blood Disorder A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leuk... More...

Myeloproliferative neoplasms, or MPNs, are a group of chronic blood cancers with the potential to rapidly progress to a more advanced stage or to an acute leukemia.

If you have been diagnosed with Myeloproliferative neoplasms (MPNs), you can rest assured that our team of experts will provide the best treatment and outcomes for you.

The Johns Hopkins Center for the Chronic Myeloproliferative Disorders coordinates the care of patients with PV and other related disorders and conducts research in these areas.

In 2005, the identification of an activating mutation in JAK2 (the V617F mutation) as a STAT5 - activating and disease - causing genetic alteration in a significant proportion of patients with myeloproliferative neoplasms (MPNs) has emphasized the oncogenic role of the JAK tyrosine kinases in hematologic malignancies.2 — 5 JAK2 is a member of the Janus tyrosine kinase family comprising three other mammalian non-receptor tyrosine kinases (JAK1, JAK3 and TYK2) that associate with cytokine receptors lacking intrinsic kinase activity to mediate cytokine - induced signal transduction and activation of STAT transcription factors.6 All JAKs share a similar protein structure and contain a tyrosine kinase domain at the C - terminus flanked by a catalytically inactive pseudokinase domain with kinase - regulatory activity, by an atypical SH2 domain and by a FERM domain that mediates association to the membrane - proximal region of the cytokine receptors.7, 8 Soon after the discovery of JAK2 V617F, we and others described that activating JAK1 mutations are relatively common in adult patients with T - cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.10

Myeloproliferative neoplasms (MPNs) are blood disorders in which the bone marrow makes too many of one or more types of blood cells — white blood cells, red blood cells or platelets.

FDA Clears Test to Help Diagnose, Identify Blood Cancer Type: The FDA has approved ClearLLab Reagents (T1, T2, B1, B2, M) for the detection of hematologic malignancies such as acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, multiple myeloma, and non-Hodgkin lymphoma.

The more recent identification of mutations in calreticulin brought with it a sense of completeness, with most patients with myeloproliferative neoplasm now having a biological basis for their excessive myeloproliferation.

Myeloproliferative neoplasms are a group of rare disorders of the bone marrow that cause an increase in the number of blood cells.

Myeloproliferative neoplasms (MPNs) are a group of related clonal hemopoietic stem cell disorders associated with hyperproliferation of myeloid cells.

There is no effective treatment for the myeloproliferative (bone marrow) form of leukemia.